Geron (GERN) Sets 2026 Financial Goals, TD Cowen Cuts PT

In different news, connected January 12, Geron Corporation (NASDAQ:GERN) shared its fiscal guidance for 2026. The institution expects RYTELO nett merchandise gross to beryllium betwixt $220 cardinal and $240 million. Total operating expenses are projected to scope from $230 cardinal to $240 million. Geron Corporation (NASDAQ:GERN) said its 2026 outlook reflects expected gross maturation on with a year-over-year simplification successful operating expenses, which it believes supports the spot of its equilibrium sheet.

For 2026, Geron Corporation (NASDAQ:GERN) said its main priorities see increasing RYTELO commercially successful the US, exploring opportunities to grow RYTELO into lower-risk myelodysplastic syndromes (LR-MDS) markets extracurricular the US, and advancing its Phase 3 IMpactMF trial.

Geron Corporation (NASDAQ:GERN) is simply a commercial-stage biopharmaceutical institution focused connected processing therapies for patients with humor cancers.

While we admit the imaginable of GERN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 AI Stocks That Are Skyrocketing and 12 Best Oil and Gas Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.